BARBARA ANN KARMANOS CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1995-01-01

Employees: 5K

Market Cap: -

Website: http://www.karmanos.org

Clinical Trials

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

Phase 2

Completed

Conditions: Myelodysplastic/Myeloproliferative Neoplasms
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Chronic Myeloproliferative Disorders
Myelodysplastic Syndromes

Interventions: Biological: rituximab
Drug: busulfan
Drug: carmustine
Drug: cyclophosphamide
Drug: cytarabine
Drug: etoposide
Drug: fludarabine phosphate
Drug: melphalan
Radiation: total body irradiation (TBI)
Drug: anti-thymocyte globulin IV

First Posted Date: 2008-06-05

Last Posted Date: 2017-06-28

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 48

Registration Number: NCT00691015

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

A Study of Biweekly Gemcitabine, Paclitaxel, and Avastin in Patients With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Paclitaxel
Drug: Gemcitabine
Drug: Avastin

First Posted Date: 2008-02-20

Last Posted Date: 2017-04-14

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 14

Registration Number: NCT00618826

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Zoledronic Acid and Positron Emission Tomography in Treating Patients With Advanced Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Metastatic Cancer
Lung Cancer

Interventions: Other: 3'-deoxy-3'-[18F]FLT
Procedure: Single photon emission computed tomography

First Posted Date: 2007-11-16

Last Posted Date: 2015-02-04

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 6

Registration Number: NCT00559897

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Bevacizumab and Docetaxel in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Biological: bevacizumab
Drug: docetaxel

First Posted Date: 2007-10-08

Last Posted Date: 2019-03-27

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 11

Registration Number: NCT00541099

Locations: 🇺🇸
Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Nevada Cancer Institute, Las Vegas, Nevada, United States

Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease

Phase 2

Completed

Conditions: Primary Systemic Amyloidosis
Light Chain Deposition Disease

Interventions: Drug: bortezomib
Drug: dexamethasone
Drug: melphalan
Genetic: microarray analysis
Other: flow cytometry
Other: laboratory biomarker analysis
Procedure: quality-of-life assessment

First Posted Date: 2007-08-27

Last Posted Date: 2023-12-22

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 35

Registration Number: NCT00520767

Locations: 🇺🇸
Providence Cancer Institute at Providence Hospital - Southfield Campus, Southfield, Michigan, United States
🇺🇸
Boston University Cancer Research Center, Boston, Massachusetts, United States
🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

and more 4 locations

Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 1

Withdrawn

Conditions: Lymphoma

First Posted Date: 2007-08-27

Last Posted Date: 2014-03-05

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Registration Number: NCT00521261

Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer

Phase 2

Completed

Conditions: Kidney Cancer
Lung Cancer
Unspecified Adult Solid Tumor, Protocol Specific
Metastatic Cancer

Interventions: Biological: sargramostim
Other: flow cytometry
Other: immunoenzyme technique
Procedure: biopsy
Procedure: cryosurgery

First Posted Date: 2007-08-09

Last Posted Date: 2020-03-05

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 8

Registration Number: NCT00514215

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer

Not Applicable

Terminated

Conditions: Breast Cancer

Interventions: Drug: erlotinib hydrochloride
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
Procedure: biopsy
Procedure: conventional surgery
Procedure: neoadjuvant therapy

First Posted Date: 2007-07-19

Last Posted Date: 2019-04-30

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 44

Registration Number: NCT00503841

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Satraplatin and Bevacizumab in Treating Patients With Metastatic Prostate Cancer Previously Treated With Docetaxel

Not Applicable

Completed

Conditions: Prostate Cancer

Interventions: Biological: bevacizumab
Drug: satraplatin

First Posted Date: 2007-07-11

Last Posted Date: 2018-06-12

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 31

Registration Number: NCT00499694

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Veterans Affairs Medical Center - Detroit, Detroit, Michigan, United States

Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma

Phase 1

Completed

Conditions: Mucositis
Multiple Myeloma

Interventions: Biological: Palifermin
Drug: melphalan
Other: questionnaire administration
Procedure: autologous peripheral blood stem cell transplantation
Other: quality-of-life assessment

First Posted Date: 2007-06-05

Last Posted Date: 2014-04-15

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 38

Registration Number: NCT00482846

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy